3D Orthobiologic Solutions
3D Orthobiologic Solutions aims to revolutionize the treatment of bone defects and diseases by developing customizable, 3D-printed scaffolds for repairing and regenerating bone in oral, maxillofacial, and orthopedic surgeries. Their platform provides an easy-to-use, biodegradable scaffold that enhances bone regrowth, reduces clinical issues, and accelerates drug discovery for bone diseases.
Industries
Nr. of Employees
small (1-50)
Products
Customizable patient-specific biodegradable bone scaffolds
3D-printed, biodegradable polymer composite scaffolds manufactured to match specific bone defect geometries for oral, maxillofacial, and orthopedic surgical applications.
Antibacterial stainless steel material technology
An antibacterial stainless steel technology acquired via acquisition of a materials research entity; positioned for use in medical device and implant applications.
Customizable patient-specific biodegradable bone scaffolds
3D-printed, biodegradable polymer composite scaffolds manufactured to match specific bone defect geometries for oral, maxillofacial, and orthopedic surgical applications.
Antibacterial stainless steel material technology
An antibacterial stainless steel technology acquired via acquisition of a materials research entity; positioned for use in medical device and implant applications.
Services
Design and prototype fabrication of patient-specific 3D-printed biodegradable scaffolds tailored to defect geometries for surgical use.
Development of three-dimensional cell culture scaffolds intended to provide physiologically relevant models for disease study and drug discovery workflows.
Design and prototype fabrication of patient-specific 3D-printed biodegradable scaffolds tailored to defect geometries for surgical use.
Development of three-dimensional cell culture scaffolds intended to provide physiologically relevant models for disease study and drug discovery workflows.
Expertise Areas
- Bone graft scaffold development
- Oral and maxillofacial implant design
- Orthopedic implant design
- Tissue engineering and biomaterials
Key Technologies
- Additive manufacturing (3D printing) for medical implants
- Biodegradable polymer composite materials
- Patient-specific CAD and scaffold geometry customization
- 3D cell culture / tissue-mimetic scaffold models
News & Updates
3D Orthobiologic Solutions successfully advanced to the final round of the RESOLVE'25 Mass Challenge Showcase, being one of twenty-five start-up finalists and one of five in the healthcare category.
The CEO and co-founder, R. Prakash Kolli, Ph.D., and Director of Engineering, Jordan Givens, completed the NIH Entrepreneurship Bootcamp, focusing on customer discovery and defining their market.
The company participated in the nineteenth cohort of the RIoT Accelerator Program, with CEO R. Prakash Kolli, Ph.D., P.E., involved in the hybrid program.
The company was featured in the RIot Accelerator Program's Startup Spotlight, sharing their journey and lessons learned.
Jeff Eardley has taken the role of Director of Growth, bringing expertise in medical device commercialization.
Selected among 128 startups from over 1300 applicants to participate in the 2024 MassChallenge U.S. Early Stage Cohort.
3D Orthobiologic Solutions successfully advanced to the final round of the RESOLVE'25 Mass Challenge Showcase, being one of twenty-five start-up finalists and one of five in the healthcare category.
The CEO and co-founder, R. Prakash Kolli, Ph.D., and Director of Engineering, Jordan Givens, completed the NIH Entrepreneurship Bootcamp, focusing on customer discovery and defining their market.
The company participated in the nineteenth cohort of the RIoT Accelerator Program, with CEO R. Prakash Kolli, Ph.D., P.E., involved in the hybrid program.
The company was featured in the RIot Accelerator Program's Startup Spotlight, sharing their journey and lessons learned.
Jeff Eardley has taken the role of Director of Growth, bringing expertise in medical device commercialization.
Selected among 128 startups from over 1300 applicants to participate in the 2024 MassChallenge U.S. Early Stage Cohort.